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ABSTRACT Primary amoebic meningoencephalitis (PAM) is a rapidly fatal infection
caused by the free-living amoeba Naegleria fowleri. The amoeba migrates along the ol-
factory nerve to the brain, resulting in seizures, coma, and, eventually, death. Previous
research has shown that Naegleria gruberi, a close relative of N. fowleri, prefers lipids
over glucose as an energy source. Therefore, we tested several already-approved inhibi-
tors of fatty acid oxidation alongside the currently used drugs amphotericin B and milte-
fosine. Our data demonstrate that etomoxir, orlistat, perhexiline, thioridazine, and val-
proic acid inhibited growth of N. gruberi. We then tested these compounds on N. fowleri
and found etomoxir, perhexiline, and thioridazine to be effective growth inhibitors.
Hence, not only are lipids the preferred food source for N. gruberi, but also oxidation of
fatty acids seems to be essential for growth of N. fowleri. Inhibition of fatty acid oxida-
tion could result in new treatment options, as thioridazine inhibits N. fowleri growth in
concentrations that can be reached at the site of infection. It could also potentiate cur-
rently used therapy, as checkerboard assays revealed synergy between miltefosine and
etomoxir. Animal testing should be performed to confirm the added value of these in-
hibitors. Although the development of new drugs and randomized controlled trials for
this rare disease are nearly impossible, inhibition of fatty acid oxidation seems a promis-
ing strategy as we showed effectivity of several drugs that are or have been in use and
that thus could be repurposed to treat PAM in the future.
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The amoeba Naegleria fowleri causes primary amoebic meningoencephalitis (PAM), arapidly fatal disease of the central nervous system (CNS) (1–3). N. fowleri is one of
the three most common free-living amoebae that can infect humans, the others being
Acanthamoeba spp. and Balamuthia mandrillaris. These amoebae are ubiquitously
present, with N. fowleri reported on all continents, except Antarctica (4). In the United
States, N. fowleri infections occur mostly in healthy children and young adults during
recreational water activities, such as swimming, diving, and rafting (5–7). In the Indian
subcontinent, the correlation with age is less clear, probably because ablution rituals,
washing, and a lack of chlorination play a large role in the epidemiology (7, 8). When
water containing N. fowleri makes contact with the nasal epithelium, the trophozoite
stage of the amoeba can migrate along the olfactory nerve, through the cribriform
plate to the olfactory bulb within the CNS (2, 3, 9). Once inside the brain, the
trophozoites cause necrosis and acute inflammation, ultimately leading to death in over
95% of the cases (1, 3). There is concern that global warming and changes in the
ecosystems that N. fowleri inhabits may lead to more cases worldwide (7, 8, 10). A wide
range of antifungals and antibiotics have been used to treat PAM with various degrees
of effectivity. Most evidence is available for amphotericin B and miltefosine, but CNS
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penetration of these drugs is poor (11–14). Because of the high mortality rate, more-
effective drugs are urgently needed (15).
Inhibition of metabolic processes essential to microorganisms is a fruitful strategy
for the development of effective drugs (16). Several widely used drugs, such as the
antimalarials atovaquone and proguanil and the broad-spectrum antiprotozoal, anti-
helminthic, and antiviral drug nitazoxanide, target the metabolism of the pathogen to
exert their killing effect (17, 18).
Previous research by our group showed that N. gruberi, a close relative of N. fowleri,
prefers fatty acids as a food source (19). This led us to the hypothesis that inhibiting
fatty acid oxidation (FAO) could inhibit growth of or even kill the amoeba. We identified
several drugs that are currently used or have been used to inhibit fatty acid metabolism
in different parts of this pathway. All of those drugs target enzymes that are present in
the N. gruberi and N. fowleri genome (19) (see also Fig. 1 and Discussion). As the fatty
acid preference was shown in N. gruberi, we first determined the effects of these
compounds on N. gruberi. We then tested promising compounds on the actual patho-
gen, N. fowleri, and finally determined whether there was synergy present when the
compounds were combined in a checkerboard assay.
RESULTS
The inhibitory effects of all compounds on N. gruberi determined through area
under the curve (AUC) calculation are represented in Fig. 2. Thioridazine (TDZ) inhibited
growth of N. gruberi in a concentration-dependent manner, inhibiting 50% of growth
at approximately 10 M (Fig. 2A). Addition of perhexiline (PHX) resulted in an inhibition
level of about 50% at concentrations above 50 M (Fig. 2B). Etomoxir (ETO) addition
resulted in clear inhibition at concentrations above 600 M (Fig. 2C), and addition of
valproic acid (VPA) resulted in inhibition of growth in a concentration-dependent
manner, with inhibition of 50% of growth at around 700 M (Fig. 2D). Orlistat (ORL)
inhibited circa 50% of growth at concentrations of 50 M and higher (Fig. 2E), and
amphotericin B (AMB) was very effective at inhibiting growth, inhibiting circa 75% at
concentrations of 0.2 M and higher (Fig. 2F). Addition of miltefosine (MIL) resulted in
FIG 1 Main pathways of energy metabolism of N. gruberi with targets of different fatty acid oxidation inhibitors
depicted as crosses. Dashed lines indicate uncertainties of the actual processes. CoA, coenzyme A.
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FIG 2 Growth curves of Naegleria gruberi were obtained in the presence or absence of inhibitors of fatty acid oxidation or drugs
currently used to treat primary amoebic meningoencephalitis. Optical density was measured daily over a 5-day period. Data
shown represent the area under the growth curve (AUC) determined for the indicated compounds and the respective controls,
including lines representing 100% and 50% of the control AUC. At the top of the graph, data representing the capacity for
regrowth are shown. , clear regrowth; /, inconsistent or little regrowth; , never any regrowth; N.D., not done. Experiments
were performed twice in triplicate wells; error bars represent standard deviations (SD).
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inhibition in a concentration-dependent manner, with efficient inhibition of growth at
80 M (Fig. 2G). The capacities for regrowth of the amoebae after 5 days of exposure
differed for the examined compounds, as can be seen in the bars above the individual
graphs in Fig. 2. Amoebae incubated with VPA and ORL showed regrowth for all
concentrations used, while PHX consistently prevented regrowth at 90 M. The amoe-
bae showed regrowth after TDZ exposure at up to a concentration of 20 M, while the
amoebae showed regrowth after ETO exposure at up to a concentration of 600 M.
Amoebae incubated with MIL showed regrowth after exposure to concentrations below
80 M and inconsistent regrowth at the examined concentrations over 80 M. AMB
was most effective in preventing regrowth, always blocking regrowth at a concentra-
tion of 0.4 M or higher (Fig. 2).
Next, the compounds were also assessed for their effect on N. fowleri. This was done
in two ways: via viability staining with CellTiter-GLO and with direct cell counting using
a flow cytometer. The 50% inhibitory (IC50) concentrations of all drugs on both
organisms are listed in Table 1. The IC50 results reported here for compounds tested on
N. gruberi represent approximations, as the range of concentrations tested was narrow.
Results of the CellTiter-GLO viability stain assay can be seen in Fig. 3, and results of cell
counting can be seen in Fig. S1 in the supplemental material. These figures show that
absence of viability and absence of cell growth were observed after exposure to TDZ,
PHX, and ETO, revealing that these compounds are effective against N. fowleri as well
as against N. gruberi. The efficacy of ETO and PHX was higher against N. fowleri than
against N. gruberi, and the IC50 levels of both drugs were about 5-fold lower against N.
fowleri than against N. gruberi. VPA and ORL showed some inhibition of N. fowleri
growth at high concentrations, but their efficacy was much lower against N. fowleri than
against N. gruberi. The effects of AMB and MIL were roughly similar against N. gruberi
and N. fowleri. The IC50 calculations show concordance between the two methods,
confirming the efficacy of the compounds against N. fowleri in two ways (Table 1). Next,
compounds were combined in these IC50 concentrations to screen for a possible
synergistic effect of combinations of compounds against N. fowleri (see Table S1 in the
supplemental material). Checkerboard assays were performed for the best six combi-
nations of the drugs, after which Fmin was calculated. The combinations MIL plus PHX,
MIL plus TDZ, MIL plus VPA, PHX plus TDZ, and TDZ plus VPA showed additivity. The
combination of ETO and MIL resulted in an F of 0.5, indicating that synergy was present
when these drugs were combined (Table S1). Further analysis of the synergistic effect
of the combination ETO and MIL with the program Combenefit resulted in a mapped
surface analysis whose results can be seen in Fig. 4. The map shows that the synergy
was most pronounced when 12.5 and 25 M concentrations of MIL were combined
with 25 to 200 M concentrations of ETO.
TABLE 1 IC50 values determined for compounds tested on Naegleria gruberi and N. fowleria
Compound Target
Naegleria gruberi Naegleria fowleri
IC50 (M)
(area under the







Thioridazine Peroxisomal lipid oxidation (26) 13 (10.6–16.0) 6.5 (5.0–8.4) 9.8 (7.3–12.9)
Perhexiline CPT-1 (28) 56 (46.6–65.3) 7.5 (6.0–9.4) 17.4 (14.9–20.4)
Etomoxir CPT-1 (29) 666 (625–708) 146.0 (114.9–185.5) 108.7 (78.2–148)
Valproic acid Acyl-CoA dehydrogenase (30) 788 (741–845) —b —
Orlistat Lipase (27) 75 (56.1–98.2) — —
Amphotericin B Sterols (15) 0.09 (0.04–0.13) 0.011 (0.007–0.016) 0.027 (0.016–0.044)
Miltefosine Unknown (43) 61 (56.5–64.7) 28.2 (23.8–33.4) 33.4 (25.6–43.0)
aN. gruberi growth curve data were obtained by measuring optical density daily over a 5-day period, after which area under the growth curve values were calculated.
The IC50 data from compounds tested on N. gruberi represent approximations, as the range of concentrations tested was narrow. N. fowleri was tested in two ways:
with CellTiter-GLO ATP stain and through cell counting with a guava EasyCyte flow cytometer. Levels of CellTiter-GLO luminescence were determined after 24 h of
incubation, and cell counts were determined after 72 h of incubation. Raw data were normalized as a percentage of the levels measured for the respective controls.
Nonlinear regression was performed by the use of GraphPad Prism 8 as [inhibitor] versus normalized response with a variable slope, after which the IC50 data were
calculated. Acyl-CoA, acyl-coenzyme A; CI, confidence interval.
b—, calculation not possible.
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FIG 3 Luminescence as a percentage of control after compound exposure to Naegleria fowleri for 24 h in 2-fold serial dilutions.
Luminescence was measured after addition of CellTiter-GLO ATP stain, in the presence or absence of inhibitors of fatty acid oxidation or
drugs currently used to treat primary amoebic meningoencephalitis. Experiments were performed in triplicate; error bars represent SD.
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Our study showed that fatty acid oxidation (FAO) inhibitors clearly inhibited growth
of both N. gruberi and N. fowleri in vitro. Hence, not only are lipids the preferred food
source for N. gruberi, but oxidation of fatty acids seems to be essential also for growth
of N. fowleri. The current treatment regimen using miltefosine (MIL) and amphotericin
B (AMB) was confirmed to be effective at inhibiting growth in vitro, which is in
agreement with previous reports (20–23) and validates our assays performed to detect
compounds that inhibit growth of Naegleria. The importance of fatty acid oxidation for
N. fowleri was demonstrated in a recent in vivo study, as Herman et al. observed
upregulation of genes of N. fowleri involved in FAO after mouse passage (24). Our
results now show that FAO inhibition is a valid target for new PAM therapy options, as
etomoxir (ETO), perhexiline (PHX), and thioridazine (TDZ) showed total growth inhibi-
tion of N. fowleri. Furthermore, our results show that there is additivity of MIL combined
with PHX, TDZ, and valproic acid (VPA) and synergy between ETO and MIL, providing
evidence that inhibition of fatty acid oxidation can be a valuable addition to the current
treatment regimen.
We observed some differences between N. gruberi and N. fowleri in the levels of
efficacy of the FAO inhibitors. All FAO inhibitors affected N. gruberi growth, but the
effects of VPA and orlistat (ORL) were much less profound on N. fowleri than on N.
gruberi. In contrast, ETO and PHX were more effective at inhibiting growth of N. fowleri
than N. gruberi. Taking the targets of the FAO inhibitors into account, we can hypoth-
esize on the reasons for these differences. The investigated FAO inhibitors affect
different enzymes involved in lipid metabolism (depicted in Fig. 1). TDZ inhibits
peroxisomal oxidation of lipids (25, 26). ORL inhibits lipases, enzymes that hydrolyze
triacylglycerol, thereby obstructing the first step in the breakdown of lipids (27). ETO
and PHX inhibit carnitine palmitoyltransferase-1 (CPT-1), blocking transport of fatty
acids into mitochondria (28, 29). Among other activities, VPA interferes mainly with
mitochondrial -oxidation (30). The targets of the FAO inhibitors are present in the N.
gruberi genome as well as in the N. fowleri genome, showing that regarding the
metabolic properties, the two organisms are very much alike (19, 31, 32). However, this
does not imply that the enzymes are exactly identical in amino acid sequence. Minor
FIG 4 Surface response plot of checkerboard assay of concentrations of etomoxir and miltefosine against
Naegleria fowleri using the BLISS model. Etomoxir and miltefosine were separately tested and combined
in 5 and 6 concentrations, respectively. Luminescence was measured after 24 h of exposure and after
addition of CellTiter-GLO ATP stain. Raw luminescence data were normalized as a percentage of the
control, results were analyzed, and the plot was generated with the combenefit program. Colors indicate
presence or absence of synergy.
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amino acid differences could result in small structural differences and hence in differ-
ences in the effects of the various drugs. Furthermore, unavoidable differences be-
tween N. fowleri and N. gruberi under in vitro growth conditions could play a role, as the
optimal culture media (PYNFH versus Bacto Casitone) and culture temperatures (25°C
versus 37°C) are different between the two, resulting in different metabolic rates.
We observed that several FAO inhibitors show additivity (PHX, TDZ, and VPA) or
synergy (ETO) when combined with MIL. Unfortunately, synergy between AMB and the
FAO inhibitors was not observed. This would be of importance, as AMB has serious side
effects (14). There is also a risk for serious adverse events when using MIL (33). We did
observe synergy between ETO and MIL, which is a promising result as this could
potentially lead to lowering of MIL dosages and subsequent reduction in the risk of
serious adverse events. ETO has been in use for some time but was retired due to its
adverse side effects in the liver. Currently, it is being repurposed as an anticancer agent
(34). Unfortunately, there are no data on the pharmacokinetics of ETO, so we do not
know the clinical applicability of ETO. We found a relatively high IC50 against N. fowleri
of approximately 100 to 150 M, but the synergy shown with MIL deserves further
investigation in an animal model.
Of all FAO inhibitors tested, TDZ showed the lowest IC50 (approximately 6 to 10 M)
against N. fowleri in our study. TDZ has been in use as an antipsychotic drug since the
early 1950s and was originally identified as a dopamine receptor 2 antagonist. Later,
TDZ was also shown to be a selective inhibitor of peroxisomal -oxidation (25, 26). It is
now being repurposed as an anticancer, anti-inflammatory, and antimicrobial agent
(35–38). The pharmacokinetics of TDZ are well studied. In a recent clinical study, the
sum of TDZ and its metabolites in serum approached 10 M (37). Furthermore, TDZ has
been shown to accumulate in brain tissue of chronically treated patients, resulting in
concentrations 10-fold higher than that in serum (39). Although AMB is effective at
nanomolar concentrations, AMB and MIL are known to have poor CNS penetration
(11–14). This could possibly explain the poor prospects for treatment of patients with
PAM and emphasizes the possible benefit of TDZ.
Development and testing of new drugs for PAM are difficult, as randomized con-
trolled trials for the treatment of PAM are impossible due to the rapidly fatal nature of
the disease and its relatively rare occurrence. Repurposing existing drugs is therefore
the most promising way to obtain additional drugs to combat PAM. There are numer-
ous examples of drugs that have been successfully repurposed to treat rare diseases
(40). All tested FAO inhibitors (including TDZ and ETO) have been or are still in clinical
use. TDZ inhibits N. fowleri growth at concentrations that can be reached at the site of
infection, and checkerboard assays revealed synergy between MIL and ETO. Further
animal testing should be performed to confirm the added value of these inhibitors.
MATERIALS AND METHODS
Chemicals and amoeba culture. N. gruberi strain NEG-M (ATCC 30224) was grown axenically at 25°C
in modified PYNFH medium (peptone, yeast extract, yeast nucleic acid, folic acid, 10% heat-inactivated
fetal bovine serum, 100 units/ml penicillin, 100 g/ml streptomycin, and 40 g/ml gentamicin) (ATCC
medium 1034), as described before (19). N. fowleri strain HB-1, kindly provided by Hana Pecková (Institute
of Parasitology, Biology Center CAS, Czech Republic), was grown axenically at 37°C in Bacto Casitone
medium. Experiments with N. fowleri were conducted at biosafety level 2 (BSL 2) according to the ATCC
guidelines and as specified by the Charles University guidelines. Bacto Casitone medium is composed of
2% Bacto Casitone, 10% heat-inactivated fetal bovine serum, penicillin (100 U/ml), and streptomycin
(100 g/ml). All experiments were performed using trophozoites harvested during logarithmic-phase
growth by repeatedly tapping cell culture flasks containing amoebae to detach trophozoites. Ampho-
tericin B (AMB), etomoxir (ETO), miltefosine (MIL), thioridazine (TDZ), orlistat (ORL), perhexiline (PHX), and
valproic acid (VPA) were purchased from Sigma. CellTiter-Glo 2.0 Cell viability assay was purchased from
Promega. Translucent flat-bottom 96-well plates were purchased from Greiner Bio-One. Black flat-bottom
96-well plates were purchased from Thermo Fisher Scientific.
Inhibition assays for N. gruberi. To screen the effects of fatty acid oxidation inhibitors and
current therapies for PAM on N. gruberi, we determined compound efficacy with optical density (OD)
measurements. Drugs were prepared as stock solutions as follows: TDZ, 10 mM in water; PHX, 50 mM
in dimethyl sulfoxide (DMSO); ETO, 10 mM in water; VPA, 20 mM in water; ORL, 35 mM in DMSO;
AMB, 10 mM in DMSO; MIL, 10 mM in water. Stock solutions were diluted in water or PYNFH medium
and added as a volume of 10 l to 1  104 N. gruberi trophozoites in 90 l of PYNFH. Compounds
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were tested per plate in triplicate in at least two independent experiments; controls contained
equivalent concentrations of compound solvents (water, PYNFH or DMSO). Plates were incubated at
25°C, and OD measurements of the contents of the 96 wells were performed every 24 h using a
FLUOstar Optima microplate reader. Regrowth capacity was assessed by collecting the whole
contents of the wells at day 5 by vigorous pipetting, after which the content (100 l) was added to
Eppendorf tubes containing 1 ml PYNFH medium. Samples were washed by centrifugation at 1,000
relative centrifugal force (rcf) and subsequent careful replacement of the supernatant with fresh
PYNFH medium. After this washing cycle was repeated three times, 1 ml supernatant was discarded
and the remaining contents were added to a new plate. Controls were diluted 10 after the washing
step to allow proper detection of regrowth in these samples. OD was measured for a further period
of 9 days of incubation at 25°C.
Inhibition assays for N. fowleri. For N. fowleri, two independent methods were used to determine
compound efficacy: a CellTiter-GLO luminescence-based ATP stain method (less sensitive to the number
of amoeba but more sensitive to viability) and cell counting by flow cytometry (sensitive to the number
of amoeba but with count determined irrespective of viability). Similar stock solutions were prepared for
N. fowleri experiments as those used for N. gruberi experiments. For CellTiter-GLO experiments, stock
solutions were diluted and added to a black 96-well plate as 10 l compound– 80 l Bacto Casitone, after
which 300 N. fowleri cells in 10 l Bacto Casitone were added to each well for a total volume of 100 l.
After 24 h of incubation at 37°C, CellTiter-GLO reagent was added and luminescence was determined by
the use of a CLARIOstar microplate reader. For flow cytometry experiments, stock solutions were diluted
and added to translucent 96-well plate wells as 20 l compound–178 l Bacto Casitone, after which 60
N. fowleri cells in 2 l Bacto Casitone were added to each well for a total volume of 200 l. After 72 h
of incubation at 37°C, paraformaldehyde was added to obtain a 1.5% concentration, after which cell
counting was performed by the use of a Guava EasyCyte flow cytometer. Appropriate gating was applied
to all samples. All experiments were performed in triplicate; all plates contained positive controls in
triplicate wells with equivalent concentrations of compound solvents (water, Bacto Casitone, or DMSO)
and negative controls without amoebae.
Checkerboards assay. Twofold dilutions were prepared of MIL (100 to 3.13 M), ETO (400 to 25 M),
PHX (25 to 1.61 M), TDZ (25 to 0.8 M), and VPA (2,000 to 62.5 M). Drugs were added to black 96-well plates
in a 5-by-6 checkerboard design as described before (41). The 96-well plates were inoculated with 300 N.
fowleri cells in Bacto Casitone per well. After 24 h of incubation at 37°C, CellTiter-GLO reagent was added and
luminescence was determined by the use of a CLARIOstar microplate reader. All experiments were performed
in triplicate; all plates contained positive controls in triplicate wells with equivalent concentrations of
compound solvents (water, Bacto Casitone, or DMSO) and negative controls without amoebae.
Data analysis. GraphPad Prism 8 was used to process data. For N. gruberi, graphs of separate wells
were constructed with OD values represented on the y axis and time (in days) on the x axis. Area under
the curve (AUC) was then calculated by the use of GraphPad Prism 8, and the calculated data were
combined into a bar chart. To determine IC50 values, results were normalized and nonlinear regression
with variable slope was performed. For N. fowleri, luminescence data and cell counts were normalized as
a percentage of the respective control, after which nonlinear regression with variable slope was
performed to determine IC50 values. To determine synergy, analysis was performed using the fractional
inhibitory concentration index (FICi), as described before (41). Briefly, FICi values were determined for the
wells with the lowest concentration of drugs that resulted in 10% luminescence of the growth control






, with Ca and Cb being the concentrations of
the drugs in the well and MICa and MICb the lowest concentrations of separate drugs that resulted in
10% of luminescence. Fmin was defined as the lowest FICi value. Additivity was determined as
0.5  FICi  2, synergy as FICi  0.5, and antagonism as FICi  2. Surface response analysis was
performed with the Combenefit program (42).
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